Literature DB >> 8063874

The metabolic topography of parkinsonism.

D Eidelberg1, J R Moeller, V Dhawan, P Spetsieris, S Takikawa, T Ishikawa, T Chaly, W Robeson, D Margouleff, S Przedborski.   

Abstract

We used [18F]fluorodeoxyglucose/positron emission tomography (18F-FDG/PET) and a statistical model of regional covariation to study brain topographic organization in parkinsonism. We studied 22 patients with Parkinson's disease (PD), 20 age-matched normal volunteers, and 10 age- and severity-matched patients with presumed striatonigral degeneration (SND). We used FDG/PET to calculate global, regional, and normalized metabolic rates for glucose (GMR, rCMRglc, rCMRglc/GMR). Metabolic parameters in the three groups were compared using an analysis of variance, with a correction for multiple comparisons, and discriminant analysis. The scaled subprofile model (SSM) was applied to the combined rCMRglc dataset to identify topographic covariance profiles that distinguish PD patients from SND patients and normals. GMR, rCMRglc, and rCMRglc/GMR were normal in PD; caudate and lentiform rCMRglc/GMR was reduced in the SND group (p < 0.01). SSM analysis of the combined group of patients and normals revealed a significant topographic profile characterized by increased metabolic activity in the lentiform nucleus and thalamus associated with decreased activity in the lateral frontal, paracentral, inferior parietal, and parietooccipital areas. Individual subject scores for this profile were significantly elevated in PD patients compared with normals and SND patients (p < 0.001) and discriminated the three groups. In the PD group, subject scores for this factor correlated with individual subject Hoehn and Yahr (H &amp; Y) scores (p < 0.02), and with quantitative rigidity (p < 0.01) and bradykinesia (p < 0.03) ratings, but not with tremor ratings. SSM analysis of right-left metabolic asymmetries yielded a topographic contrast profile that accurately discriminated mildly affected PD patients (H &amp; Y Stage I) from normals. Our findings demonstrate that abnormal topographic covariance profiles exist in parkinsonism. These profiles have potential clinical application as neuroimaging markers in parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8063874     DOI: 10.1038/jcbfm.1994.99

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  116 in total

1.  Usefulness of a dopamine transporter PET ligand [(18)F]beta-CFT in assessing disability in Parkinson's disease.

Authors:  J O Rinne; H Ruottinen; J Bergman; M Haaparanta; P Sonninen; O Solin
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-12       Impact factor: 10.154

Review 2.  Neuroimaging in Parkinson's disease.

Authors:  A Jon Stoessl
Journal:  Neurotherapeutics       Date:  2011-01       Impact factor: 7.620

3.  Event based and time based prospective memory in Parkinson's disease.

Authors:  S Katai; T Maruyama; T Hashimoto; S Ikeda
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

Review 4.  Neurodegeneration: what is it and where are we?

Authors:  Serge Przedborski; Miquel Vila; Vernice Jackson-Lewis
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

Review 5.  The development, past achievements, and future directions of brain PET.

Authors:  Terry Jones; Eugenii A Rabiner
Journal:  J Cereb Blood Flow Metab       Date:  2012-03-21       Impact factor: 6.200

6.  The organization and anatomy of narrative comprehension and expression in Lewy body spectrum disorders.

Authors:  Sharon Ash; Sharon X Xie; Rachel Goldmann Gross; Michael Dreyfuss; Ashley Boller; Emily Camp; Brianna Morgan; Jessica O'Shea; Murray Grossman
Journal:  Neuropsychology       Date:  2012-02-06       Impact factor: 3.295

Review 7.  Chronic MPTP administration regimen in monkeys: a model of dopaminergic and non-dopaminergic cell loss in Parkinson's disease.

Authors:  Gunasingh J Masilamoni; Yoland Smith
Journal:  J Neural Transm (Vienna)       Date:  2017-08-31       Impact factor: 3.575

8.  Deficient supplementary motor area at rest: Neural basis of limb kinetic deficits in Parkinson's disease.

Authors:  Stefanie Kübel; Katharina Stegmayer; Tim Vanbellingen; Sebastian Walther; Stephan Bohlhalter
Journal:  Hum Brain Mapp       Date:  2018-05-02       Impact factor: 5.038

9.  Changes in network activity with the progression of Parkinson's disease.

Authors:  Chaorui Huang; Chengke Tang; Andrew Feigin; Martin Lesser; Yilong Ma; Michael Pourfar; Vijay Dhawan; David Eidelberg
Journal:  Brain       Date:  2007-04-30       Impact factor: 13.501

Review 10.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.